
A Laboratory-Based Examination of the Potential for Fugitive Emission of Aerosols to the Local Environment from a Range of Commercially Available Nebulizer Systems

M. Nagel¹, J.A. Suggett¹, J.P. Mitchell²

¹Trudell Medical International, London, Ontario, Canada ²Jolyon Mitchell Inhaler Consulting Services Inc.

BACKGROUND

- An unintended consequence with inhaled medication from nebulizing systems is the potential for fugitive emission during treatment
- There exists a potential risk factor in both clinical and home care settings, particularly in the context of the present COVID-19 pandemic



PURPOSE


 Compare the potential for fugitive emission from a variety of widely encountered nebulizers during simulated adult tidal breathing

MATERIALS & METHODS

Patient Simulation

- 3 mL of albuterol (2.5 mg / 3 mL) used as the tracer aerosol
- The mouthpiece of the nebulizer-on-test was connected to an ASL 5000 (IngMar Medical), set to simulate realistic variations in inspiratory/ expiratory (I:E) ratio associated with different patients' disease states


Tidal Volume (mL)	Respiration Rate (cycles/min)	I:E Ratio	Example Condition
500	15	1:1	Intervention to improve arterial oxygenation
	10	1:2	Normal adult respiration
	7	1:3	Slight/Moderate obstructive disease
	6	1:4	Severe obstructive disease



Nebulizer


- A filter was placed at the nebulizer mouthpiece and replaced after every minute of nebulization. The process repeated until sputter occurred
- 10 commonly available small volume nebulizers (SVNs) were tested jet, breath actuated, and vibrating mesh

Calculated Loss:



RESULTS

Variation of Environmental Loss of Albuterol Tracer, Showing the Influence of Inspiratory/Expiratory Ratio



- Wide variations in total dose observed with different nebulizer types (see abstract)
- Considerable variations in L_{env} across different nebulizer systems
- Lenv was influenced by the change in I:E ratio, increasing with an increase in the length of the exhalation phase

CONCLUSIONS

Summary of Key Findings

- A wide variation in total dose across the different nebulizer types – a feature that is consistent with previous laboratory-based comparisons¹
- Growing L_{env} as a proportion of exhalation time, given that more time is proportionately available for fugitive emission generation

Breath-actuation
(AeroEclipse® II BAN™
Nebulizer) substantially
reduced Lenv but did not
completely eliminate it

Future Directions

 These findings could help develop policies and best practices for the risk mitigation of fugitive emissions from nebulizing systems

¹ JL Rau, A Ari, RD Restrepo: Performance Comparison of Nebulizer Designs: Constant-Output, Breath-Enhanced, and Dosimetric. Respiratory Care 2004;49(2):174-179.





May 4-7, 2021

